Brian Stuglik, Verastem CEO
Verastem touts mid-stage data in rare type of ovarian cancer: #ASCO23
Verastem says its drug combination led to responses in nearly half of patients with a rare type of ovarian cancer that grows slowly but is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
